Skip to main content

Table 7 Survival of PSP cases by NAT2 phenotype

From: Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

NAT2 Phenotype

Median(Min, Max)

Mean(SD)

p-values

Age at Onset

   

Rapid

68.5(51,85)

68.5(8.5)

> 0.05

Intermediate

68(41,89)

68.1(8.6)

> 0.05

Slow

68(47,90)

67.9(8.1)

--

Age at Death

   

Rapid

75.5(58,89)

75.3(7.9)

> 0.05

Intermediate

76(44,98)

75.3(8.3)

> 0.05

Slow

76(53,95)

75.4(7.9)

--

Disease Duration (yrs.)

   

Rapida

6(2,12)

6.6(2.2)

0.025, 0.078, 0.028

Intermediateb

7(2,31)

7.4(3.6)

0.675

Slow

7(0,27)

7.5(3.3)

--

  1. Pairwise comparisons of age at onset, age at death, and disease duration by NAT2 phenotype (t-test with unequal variances). ap-values = rapid vs. slow, rapid vs. intermediate, rapid vs. slow + intermediate, respectively. bp-value = slow vs. intermediate. Overall p-values from Wilcoxon rank sum tests were all > 0.1